Company-reported prevalence
Imsidolimab
Overview
| Field | Value |
|---|---|
| Drug | Imsidolimab |
| Indication | Generalized pustular psoriasis |
| Disease | Generalized pustular psoriasis (GPP) |
| Company | Vanda Pharmaceuticals Inc. (exclusive global license to develop, manufacture, and commercialize, February 2025); AnaptysBio, Inc. (licensor and developer before February 2025; royalty on global net sales) |
| Documents searched | Vanda: corporate website home and products and pipeline pages (accessed October 2026); press releases naming imsidolimab, February 2025 to July 2026; Form 10-K for 2025 (February 2026); Form 10-Q for the second quarter of 2026 (August 2026); corporate presentation (September 2026). AnaptysBio: press releases naming imsidolimab, October 2023 to February 2025; Form 10-K for 2024 (February 2025); Form 10-K for 2023 (March 2024); Form 10-Q for the first quarter of 2024 (May 2024); corporate presentations (January 2024; January 2026) |
| Data as of | October 14, 2026 |
| Prepared by | AI research agent (Claude); not yet reviewed by a person |
Company statements of prevalence
United States
Number diagnosed (at least one GPP diagnosis code): AnaptysBio corporate presentation, January 2024
Cited source: 2.4 IQVIA, undated
(opens the full-size image in a new tab)Number diagnosed (two or more GPP diagnosis codes): AnaptysBio corporate presentation, January 2024
Cited source: 2.4 IQVIA, undated
(opens the full-size image in a new tab)Europe
No evidence found.
Global
Prevalence: Vanda Pharmaceuticals press release, February 2026
Cited source: 2.2 Sachen 2022; 2.1 Prinz 2022
(opens the full-size image in a new tab)Prevalence: Vanda Pharmaceuticals and AnaptysBio press release, February 2025
Cited source: 2.1 Prinz 2022
(opens the full-size image in a new tab)Other countries and regions
Number diagnosed: Vanda Pharmaceuticals press release, May 2026
Geography not stated
No evidence found.
Sources the company cites
Prinz 2022
Reference as the company lists it, press release, February 25, 2026
Reference as the company lists it, press release, February 3, 2025
Passage carrying the figure
Sachen 2022
Passage carrying the figure
Not quoted: The publisher's full text was not reachable (the ScienceDirect page returned a human-verification challenge); the PubMed abstract describes IL-36 biology and states no prevalence figure.
Japan intractable diseases information center 2026
Reference as the company lists it
Passage carrying the nearest figure
IQVIA, undated
Passage carrying the figure
Not quoted: The company names a proprietary claims analysis by IQVIA and no published document; no document reporting the analysis was located.
References
- AnaptysBio (2024) corporate presentation, January 2024 (opens in a new tab)
- Japan Intractable Diseases Information Center (2026) Pustular psoriasis (generalized type), Designated Intractable Disease 37 (opens in a new tab)
- Prinz 2022 (opens in a new tab)
- Sachen 2022 (opens in a new tab)
- Vanda Pharmaceuticals (2025) press release, February 3, 2025 (opens in a new tab)
- Vanda Pharmaceuticals (2026) press release, February 25, 2026 (opens in a new tab)
- Vanda Pharmaceuticals (2026) press release, May 27, 2026 (opens in a new tab)